Send Press Release To Your Friends

PR Title:	Novartis application for expanded Menveo® indication from 2 months of age accepted for review by FDA
PR Summary:	Novartis announced today that the US Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) to expand the Menveo® (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) indication to include infants and toddlers from 2 months of age.

	Basic Information
	Your Name* Your Email* Friend's Name Friend's Email 1* 2   3   Your Message